NASDAQ:MYNZ Mainz Biomed (MYNZ) Stock Price, News & Analysis $0.36 +0.01 (+4.29%) (As of 11:19 AM ET) Add Compare Share Share Today's Range$0.36▼$0.4050-Day Range$0.35▼$0.9052-Week Range$0.32▼$5.01Volume143,944 shsAverage Volume163,255 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Mainz Biomed alerts: Email Address Mainz Biomed MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,638.1% Upside$6.00 Price TargetShort InterestHealthy1.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.45 out of 5 stars 3.3 Analyst's Opinion Consensus RatingMainz Biomed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMainz Biomed has only been the subject of 1 research reports in the past 90 days.Read more about Mainz Biomed's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.65% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 33.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MYNZ. Previous Next 2.8 News and Social Media Coverage News SentimentMainz Biomed has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Mainz Biomed this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for MYNZ on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Read more about Mainz Biomed's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mainz Biomed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsURGENT: Another Country Abandons the DollarVietnam just ditched the US dollar. And they're not alone. BRICS nations are rapidly moving away from the greenback, threatening the stability of your retirement savings. Your wealth could vanish overnight.GET YOUR FREE REPORT HERE >>> About Mainz Biomed Stock (NASDAQ:MYNZ)Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Read More MYNZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYNZ Stock News HeadlinesJuly 2 at 8:01 AM | globenewswire.comMainz Biomed Provides Half Year 2024 Corporate UpdateJune 28, 2024 | americanbankingnews.comMainz Biomed (NASDAQ:MYNZ) Sees Large Decrease in Short InterestJuly 2, 2024 | Behind the Markets (Ad)[Breaking] Classified Wargames Reveal Grave Threat from ChinaThe economic fallout could be devastating for unprepared investors. But sectors like aerospace & defense may see soaring demand. Don't be caught off guard - get the details on the weapons makers set to boom if war breaks out.June 3, 2024 | globenewswire.comMainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024May 31, 2024 | globenewswire.comMainz Biomed Reports Results of 2024 Annual General MeetingMay 28, 2024 | finanznachrichten.deEQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert neue gepoolte Daten seiner bisher größten Darmkrebs-Screening-Studie auf der ASCO 2024May 28, 2024 | globenewswire.comMainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual MeetingMay 20, 2024 | globenewswire.comMainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA TrialJuly 2, 2024 | Behind the Markets (Ad)[Breaking] Classified Wargames Reveal Grave Threat from ChinaThe economic fallout could be devastating for unprepared investors. But sectors like aerospace & defense may see soaring demand. Don't be caught off guard - get the details on the weapons makers set to boom if war breaks out.May 7, 2024 | finanznachrichten.deEQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease Week 2024May 7, 2024 | globenewswire.comMainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.April 30, 2024 | uk.news.yahoo.comStrictly Come Dancing's Shirley Ballas shares important cancer update to fansApril 25, 2024 | globenewswire.comMainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer DiagnosticApril 17, 2024 | msn.comMainz Biomed N.V. (MYNZ) Price Target Decreased by 9.09% to 5.10April 10, 2024 | finance.yahoo.comThe Pharmaceutical Industry Finds Itself At A Historical CrossroadsApril 9, 2024 | investorplace.comMYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023April 9, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Reports Full Year 2023 Financial ResultsApril 9, 2024 | globenewswire.comMainz Biomed Reports Full Year 2023 Financial ResultsApril 5, 2024 | seekingalpha.comMYNZ Mainz Biomed N.V.April 2, 2024 | benzinga.comPharma's Post-Pandemic Story To Unlock A Cancer-Free EraMarch 19, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer TreatmentMarch 19, 2024 | globenewswire.comMainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer TreatmentMarch 18, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic OptionsMarch 18, 2024 | globenewswire.comMainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic OptionsMarch 12, 2024 | finanznachrichten.deMainz BioMed NV: Mainz Biomed Presents ColoAlert at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening InnovationsMarch 12, 2024 | globenewswire.comMainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening InnovationsMarch 5, 2024 | globenewswire.comMainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer DiagnosticSee More Headlines Receive MYNZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/09/2024Today7/01/2024Next Earnings (Estimated)7/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MYNZ CUSIPN/A CIK1874252 Webmainzbiomed.com Phone49-6131-554-2860FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,638.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,300,000.00 Net Margins-2,934.82% Pretax Margin-2,938.10% Return on Equity-488.05% Return on Assets-145.77% Debt Debt-to-Equity Ratio0.36 Current Ratio0.97 Quick Ratio0.91 Sales & Book Value Annual Sales$900,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book1.28Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.15 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Guido Baechler (Age 59)CEO & Executive Director Mr. William J. Caragol (Age 57)Chief Financial Officer Dr. Christopher Von Torne P.M.P. (Age 52)Ph.D., Chief Operating Officer Dr. Frank Krieg-Schneider (Age 62)Chief Technology Officer Dr. Moritz Eidens Ph.D. (Age 40)Chief Science Officer & Executive Director Stefan ErlachHead of Human ResourcesMr. Philipp Freese (Age 41)Chief Business Officer Mr. Darin S. Leigh (Age 56)Chief Commercial Officer More ExecutivesKey CompetitorsLAVA TherapeuticsNASDAQ:LVTXNLS PharmaceuticsNASDAQ:NLSPOncoSec MedicalNASDAQ:ONCSQPharvarisNASDAQ:PHVSProcaps GroupNASDAQ:PROCView All Competitors MYNZ Stock Analysis - Frequently Asked Questions Should I buy or sell Mainz Biomed stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mainz Biomed in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MYNZ shares. View MYNZ analyst ratings or view top-rated stocks. What is Mainz Biomed's stock price target for 2024? 2 analysts have issued 1-year target prices for Mainz Biomed's shares. Their MYNZ share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,638.1% from the stock's current price. View analysts price targets for MYNZ or view top-rated stocks among Wall Street analysts. How have MYNZ shares performed in 2024? Mainz Biomed's stock was trading at $1.16 on January 1st, 2024. Since then, MYNZ shares have decreased by 70.2% and is now trading at $0.3452. View the best growth stocks for 2024 here. Are investors shorting Mainz Biomed? Mainz Biomed saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 282,200 shares, a decline of 33.7% from the May 31st total of 425,700 shares. Based on an average trading volume of 206,100 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.7% of the company's stock are short sold. View Mainz Biomed's Short Interest. When is Mainz Biomed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 2nd 2024. View our MYNZ earnings forecast. How were Mainz Biomed's earnings last quarter? Mainz Biomed (NASDAQ:MYNZ) announced its earnings results on Tuesday, April, 9th. The company reported ($0.24) EPS for the quarter. The company had revenue of $0.22 million for the quarter. Mainz Biomed had a negative net margin of 2,934.82% and a negative trailing twelve-month return on equity of 488.05%. When did Mainz Biomed IPO? Mainz Biomed (MYNZ) raised $10 million in an initial public offering (IPO) on Friday, November 5th 2021. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities served as the underwriter for the IPO. How do I buy shares of Mainz Biomed? Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MYNZ) was last updated on 7/2/2024 by MarketBeat.com Staff From Our PartnersNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredThe Only Retirement Stock You'll Ever Need? Discover NowThere is a little region of America called Loudoun County. The value of each square mile has shot up close ...Behind the Markets | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden’s inner circle turns against him?On August 19, the Democratic party will take the stage in Chicago and officially nominate their presidential c...Paradigm Press | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
